ANGO - アンジオダイナミクス (AngioDynamics Inc.) アンジオダイナミクス



symbol ANGO
会社名 AngioDynamics Inc (アンジオダイナミクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 アンジオダイナミクス(AngioDynamics Inc.)は血管アクセス、末梢血管疾患の治療、腫瘍学および外科手術環境での使用のために、専門の医療提供者によって使用される医療、外科と診断装置を設計、製造および販売する。同社のデバイスは低侵襲イメージガイド付きの手順に使用される。同社は、末梢血管、血管アクセスおよび腫瘍・外科の3つの製品グルーピング製品を提供する。同社の末梢血管製品には、流体管理、静脈、血栓管理等の主要製品が含まれる。同社のBioFlo製品は、Endexo技術を血管アクセス製品の製造・設計に組み込む。同社の腫瘍・外科製品にはマイクロ波アブレーション製品、ラジオ波アブレーション(RFA)、NanoKnife製品ラインなどを含む。   アンジオダイナミクスは米国の医療機器メ―カ―。末梢血管疾患の治療や手術に使用される医療機器の開発、製造、販売を行う。同社の製品は高周波焼灼術用機器、NanoKnifeの他、血管アクセス製品、血管造影製品、透析製品、血管形成術製品、排水製品、血栓溶解製品、塞栓製品、静脈製品や腎臓治療の製品など。本社はニューヨーク州レ―サム。   AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.
本社所在地 14 Plaza Drive Latham NY 12110 USA
代表者氏名 Howard W. Donnelly ハワード・W・ドネリー
代表者役職名 Independent Chairman of the Board
電話番号 +1 518-798-1215
設立年月日 1988年
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 1145人
EBITDA EBITDA(百万ドル) 50.57800
終値(lastsale) 20.455
時価総額(marketcap) 759322900.74
時価総額 時価総額(百万ドル) 755.42510
売上高 売上高(百万ドル) 344.21400
企業価値(EV) 企業価値(EV)(百万ドル) 819.75710
当期純利益 当期純利益(百万ドル) 8.50100
決算概要 決算概要 BRIEF: For the three months ended 31 August 2018 AngioDynamics Inc. revenues decreased less than 1% to $85.3M. Net loss increased from $35K to $469K. Revenues reflect Vascular Access segment increase of 2% to $23.8M Peripheral Vascular segment increase of less than 1% to $50M International segment increase of 7% to $17.7M also reflect Oncology/Surgery segment decrease of 6% to $11.6M United States segment decrease of 2% to $67.7M.



   Interventional Radiology Devices Market to See Huge Growth by 2027 : Guerbet, Medtronic, Biotronik  2022/08/08 18:25:00 SBWire
New Jersey, USA -- ( SBWIRE ) -- 08/08/2022 -- The latest study released on the Global Interventional Radiology Devices Market by AMA Research evaluates market size, trend, and forecast to 2027. The Interventional Radiology Devices market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in This Report Include: Abbott (United States), B. Braun (Germany), Boston Scientific (United States), Koninklijke Philips (Netherlands), Cardinal Health (United States), Medtronic (Ireland), Alvimedica (Turkey), Guerbet (France), Angiodynamics (United States), Balton (Poland) and Brosmed Medical (China). Additionally, following companies can also be profiled that are part of our coverage like Biosensors (Switzerland), Biotronik (Germany), Cook Medical (United States) and Endocor (Germany) Download Sample Report PDF (Including Full TOC, Table & Figures) @ Definition: Image-guided surgery seems to be what interventional radiology is all about.
   AngioDynamics to Present at the Canaccord Genuity Growth Conference  2022/08/03 20:01:00 Business Wire
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference at 2:00 p.m. ET on Wednesday, August 10, 2022. A live webcast
   AngioDynamics: Growth Is Encouraging, But Margins Still A Work In Progress (NASDAQ:ANGO)  2022/07/14 03:32:08 Seeking Alpha
AngioDynamics posted better sales growth in FQ4''22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly.
   Raymond James Cuts Price Target On AngioDynamics  2022/07/13 18:51:15 Benzinga
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO ) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued execution, supporting the Strong Buy rating. The revenue momentum is real and will carry into F23 (guide of 8-10% growth), the analyst wrote. He views back-order fulfillment as a … Full story available on
   AngioDynamics: Deflationary Tailwinds From Price Inputs, Yet Lack Of Upside To Capture  2022/07/13 03:39:44 Seeking Alpha
AngioDynamics presents with deflationary tailwinds bought on by a softening in key materials used in its manufacturing process.
   Endovenous Laser Therapy Market Growth Analysis and Key Business Strategies 2027| AngioDynamics, Syneron, Dornier  2021/12/09 08:56:02 OpenPR
Los Angeles, United State: The global Endovenous Laser Therapy market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section
   Citadel Advisors LLC Cuts Stake in AngioDynamics, Inc. (NASDAQ:ANGO)  2021/12/06 09:26:43 Dakota Financial News
Citadel Advisors LLC cut its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 35.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,644 shares of the medical instruments suppliers stock after selling 37,414 shares during the quarter. Citadel Advisors LLCs holdings []
   AngioDynamics (NASDAQ:ANGO) Downgraded by Zacks Investment Research  2021/12/05 07:44:42 Dakota Financial News
Zacks Investment Research lowered shares of AngioDynamics (NASDAQ:ANGO) from a strong-buy rating to a hold rating in a research report report published on Wednesday, reports. The brokerage currently has $27.00 target price on the medical instruments suppliers stock. According to Zacks, AngioDynamics uptick in year-over-year revenues and solid performances across two of its GBUs []
   AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Comerica Bank  2021/12/02 11:56:41 Dakota Financial News
Comerica Bank trimmed its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 7.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,852 shares of the medical instruments suppliers stock after selling 2,877 shares during the quarter. Comerica Banks holdings in AngioDynamics were worth []
   AngioDynamics (NASDAQ:ANGO) Stock Rating Lowered by Zacks Investment Research  2021/12/02 10:20:42 Transcript Daily
Zacks Investment Research cut shares of AngioDynamics (NASDAQ:ANGO) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday, reports. The brokerage currently has $27.00 price objective on the medical instruments suppliers stock. According to Zacks, AngioDynamics uptick in year-over-year revenues and solid performances across two of its []
   Stock trading in red: AngioDynamics, Inc. (NASDAQ: ANGO)  2021/07/14 17:00:46 FXDailyReport
AngioDynamics, Inc. (NASDAQ: ANGO) stock fell over 2.7% on 14th July, 2021 (As of 12:58:52 UTC-4 · USD; Source: Google finance) post fourth quarter of The post Stock trading in red: AngioDynamics, Inc. (NASDAQ: ANGO) appeared first on FXDailyReport.Com .
   The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues  2021/07/14 11:48:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) (IPOed Tuesday) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc.
   AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript  2021/07/13 16:53:07 Seeking Alpha
   AngioDynamics shares rise on Q4 topline beat, FY forecast  2021/07/13 14:10:26 Seeking Alpha
   Angiodynamics Inc (ANGO) Q4 2021 Earnings Call Transcript  2021/07/13 13:51:53 AlphaStreet
Angiodynamics Inc (NASDAQ: ANGO) Q4 2021 earnings call dated Jul. 13, 2021 Presentation: Operator Good morning, and welcome to the AngioDynamics Fourth Quarter and Fiscal Year 2021 Earnings Call. [Operator [] The post Angiodynamics Inc (ANGO) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 アンジオダイナミクス ANGO AngioDynamics Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)